Factors affecting sufentanil consumption for intravenous controlled analgesia after hepatectomy: retrospective analysis

• Published in: BMC anesthesiology Vol. 21; no. 1; p. 308
• Main Authors: Wu, Yue, Tian, Lina, Li, Chunye, Liu, Minjun, Qiao, Shina, Zhang, Weibo, Tian, Suming, Chen, Gang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07-12-2021; BioMed Central; BMC
• Subjects: Age; Age Factors; Aged; Analgesia; Analgesia, Patient-Controlled - methods; Analgesics; Analgesics, Opioid - administration & dosage; Analgesics, Opioid - therapeutic use; Analysis; Anesthesia; Body mass index; Cancer surgery; Care and treatment; Dosage; Drug dosages; Erythrocytes; Female; Hepatectomy; Hepatectomy - methods; Humans; Independent sample; Influencing factors; Intravenous administration; Laboratories; Laparoscopy; Liver; Liver cancer; Male; Medical research; Medicine, Experimental; Middle Aged; Narcotics; Nonsteroidal anti-inflammatory drugs; Operative Time; Opioids; Pain; Pain perception; Pain, Postoperative - drug therapy; Patient satisfaction; Patient-controlled analgesia; Patients; Pharmaceuticals; Physiological aspects; Postoperative pain; Retrospective Studies; Risk Factors; Sufentanil; Sufentanil - administration & dosage; Sufentanil - therapeutic use; Sufentanil consumption; Surgery; Urea; United States > US; China; Germany; Postoperative pain; Sufentanil consumption; Influencing factors; Patient-controlled analgesia; Hepatectomy
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-021-01526-z

Pain control after hepatectomy is usually achieved by opioids. There are significant individual differences in the amount of opioids used after hepatectomy, and the metabolism of opioids is liver-dependent. The purpose of our study was to explore the possible risk factors for opioid consumption during the first 48 h after surgery.
In a retrospective study design involving 562 patients undergoing open or laparoscopic hepatectomy, all patients were treated with intravenous patient-controlled analgesia (IV-PCA) along with continuous and bolus doses of sufentanil for a duration of 48 h after surgery during the time period of August 2015 and February 2019. The primary endpoint was high sufentanil consumption 48 h after hepatectomy, and patients were divided into two groups: those with or without a high PCA sufentanil dosage depending on the third quartile (Q3). The secondary endpoint was the effect of a high PCA sufentanil dosage on various possible clinical risk factors. The relevant parameters were collected, and correlation and multivariate regression analyses were performed.
The median operation time was 185 min (range, 115-250 min), and the median consumption of sufentanil 48 h after the operation was 91 μg (IQR, 64.00, 133.00). Factors related to the consumption of sufentanil at 48 h after hepatectomy included age, operation time, blood loss, intraoperative infusion (red blood cells and fresh-frozen plasma), pain during movement after surgery (day 1 and day 2), preoperative albumin, and postoperative blood urea nitrogen. Age (≤ 60 and > 60 years), extent of resection (minor hepatic resection and major hepatic resection), surgical approach (laparoscope and open) and operation time (min) were independent risk factors for sufentanil consumption at 48 h postoperatively.
Age younger than 60 years, major hepatic resection, an open approach and a longer operation are factors more likely to cause patients to require higher doses of sufentanil after hepatectomy, and the early identification of such patients can increase the efficacy of perioperative pain management.